Drugs / aviscumine
aviscumine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00932724 | Jul 2009 → Aug 2012 | colorectal cancer | Cytavis Biopharma GmbH | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00658437 | Apr 2008 → Aug 2009 | melanoma | Cytavis Biopharma GmbH | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aviscumine | “Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study.” PMID 25324973 ↗ Aug 2014 |
| Known as | Aviscumina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108170 ↗ |
| Known as | CY-503 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00932724 ↗ |
| Known as | Mistletoe lectins aviscumine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108170 ↗ |
| Modality | Protein / enzyme biologic | “Aviscumine, a recombinant plant protein, is an immune modulator” PMID 25324973 ↗ Aug 2014 |
| Route | Subcutaneous | “350 ng aviscumine twice weekly by subcutaneous injection” PMID 25324973 ↗ Aug 2014 |